Company / Working Capital
Organon & Co. Working Capital History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$2.0B
FY2025
5-year range
$1.2B / $2.0B
FY2021-FY2025
Trend
+20.4%
vs FY2024
Sector context
#20 of 213
Health Care
What the data says
Among 213 Health Care companies, Organon & Co. is in the top 9% for working capital. Working Capital has increased for 5 consecutive years, from $894M in FY2020 to $2.0B in FY2025.
Based on SEC 10-K filings.
$2.0B in FY2025 with a 5-year CAGR of +17.0%. Top quartile in the Health Care sector.
Improved from $1.6B to $2.0B over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- +11.4%
- 5-Year CAGR
- +17.0%
- 10-Year CAGR
- -
Sector benchmark
Top 9% in Health CareTop 9% of 213This company $2.0B Sector average $934.6M
▼
+109.9% above sector average
Key checks
Key Insights
- Organon & Co.'s working capital has grown for 5 consecutive years.
- 5-year CAGR of +17.0%, indicating consistent growth.
- In FY2025, working capital increased 20.4% year-over-year.
- Ranks #20 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.69 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
- Strong return on equity: 55.3%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.0B | +20.4% |
| FY2024 | $1.6B | +2.5% |
| FY2023 | $1.6B | +12.1% |
| FY2022 | $1.4B | +22.0% |
| FY2021 | $1.2B | +30.1% |
| FY2020 | $894.0M | - |
| FY2019 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026